Scarica l'app Stockscreener
7.05
0.43%
0.03
Dopo l'orario di chiusura:
7.07
0.02
+0.28%
Precedente Chiudi:
$7.02
Aprire:
$6.895
Volume 24 ore:
1.65M
Relative Volume:
0.68
Capitalizzazione di mercato:
$557.31M
Reddito:
$311.71M
Utile/perdita netta:
$163.05M
Rapporto P/E:
3.5543
EPS:
1.9835
Flusso di cassa netto:
$172.79M
1 W Prestazione:
+5.22%
1M Prestazione:
-2.22%
6M Prestazione:
-36.20%
1 anno Prestazione:
+11.90%
Intervallo 1D:
$6.82
$7.065
Intervallo di 1 settimana:
$6.56
$7.065
Portata 52W:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Nome
CorMedix Inc
Settore
Industria
Telefono
908-517-9500
Indirizzo
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.05 | 557.31M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Leerink Partners | Outperform |
| 2025-01-13 | Iniziato | D. Boral Capital | Buy |
| 2024-08-26 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-02-17 | Iniziato | Needham | Buy |
| 2020-09-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-09-21 | Iniziato | Truist | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2019-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2018-12-06 | Iniziato | ROTH Capital | Buy |
| 2017-09-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-08-10 | Reiterato | Rodman & Renshaw | Buy |
| 2017-05-05 | Reiterato | Rodman & Renshaw | Buy |
| 2016-11-11 | Reiterato | FBR & Co. | Outperform |
| 2016-03-17 | Reiterato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | FBR Capital | Outperform |
| 2015-11-16 | Reiterato | ROTH Capital | Neutral |
| 2015-10-29 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Reiterato | ROTH Capital | Buy |
| 2011-10-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
CorMedix Inc Borsa (CRMD) Ultime notizie
RSI Check: What makes CorMedix Inc stock attractive todayWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Trading Systems Reacting to (CRMD) Volatility - Stock Traders Daily
CorMedix Inc. (CRMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) (NASDAQ:CRMD) - Seeking Alpha
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Quarterly Risk: What makes CorMedix Inc stock attractive today2026 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
CRMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast? - MSN
CorMedix Q4 2025 Earnings Call Transcript - MarketBeat
Market Trends: Why is CorMedix Inc stock going downQuarterly Investment Review & Community Consensus Trade Alerts - baoquankhu1.vn
CorMedix soars on increased Q2 sales guidance - MSN
Aug Update: Why is CorMedix Inc stock going downQuarterly Risk Review & Long-Term Growth Stock Strategies - baoquankhu1.vn
Vanguard disaggregates holdings; reports 0% in CorMedix (CRMD) - Stock Titan
Do Options Traders Know Something About CorMedix Stock We Don't? - Zacks Investment Research
How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset - Yahoo Finance
How Cormedix Inc. (CRMD) Affects Rotational Strategy Timing - Stock Traders Daily
Levels Update: Can CorMedix Inc outperform under higher oil pricesWeekly Stock Analysis & Free Accurate Trade Setup Notifications - baoquankhu1.vn
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines? - simplywall.st
US Market Recap: What is the target price for CorMedix Inc stock2026 Stock Rankings & Daily Profit Focused Stock Screening - baoquankhu1.vn
Street Watch: Is CorMedix Inc a stock for growth or value investors2026 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Shorts: What makes CorMedix Inc stock attractive todayWeekly Trend Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
Why did CRMD stock tumble over 11% today? - MSN
CorMedix at Citizens Life Sciences: Strategic Expansion and Growth By Investing.com - Investing.com Canada
CRMD: REZZAYO and DefenCath drive growth, with Melinta boosting revenue and new markets targeted - TradingView
CorMedix at Leerink Conference: Strategic Evolution and Market Potential By Investing.com - Investing.com Nigeria
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead - TipRanks
CorMedix at Leerink Conference: Strategic Evolution and Market Potential - Investing.com
CRMD: Diversified specialty pharma advancing REZZAYO and DefenCath, with strong growth catalysts ahead - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com Nigeria
What is CorMedix Inc.’s book value per shareMarket Weekly Review & Fast Moving Stock Trade Plans - baoquankhu1.vn
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? - MSN
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit SwingWhat's Changed - simplywall.st
CorMedix Q4 2025 earnings preview - MSN
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix (CRMD) lags Q4 earnings estimates - MSN
CorMedix Therapeutics 2026: Portfolio Expansion, Financial Highlights, DefenCath Launch & Growth Pipeline in Specialty Pharma 1234567 - Minichart
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - MSN
CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio - MSN
Leerink cuts CorMedix stock price target on expense adjustments - Investing.com India
Update Recap: What is the target price for CorMedix Inc stockWeekly Risk Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
CorMedix 2025 Financial Results: $163.1M Profit, $311.7M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
CorMedix Reaffirms DefenCath 2027 Sales and Outlook - TipRanks
Leerink cuts CorMedix stock price target on expense adjustments By Investing.com - Investing.com South Africa
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations - Yahoo Finance
CorMedix Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
CorMedix Inc. (NASDAQ:CRMD) Q4 2025 Earnings Call Transcript - Insider Monkey
Cormedix Earnings Review: Q4 Summary - Sahm
CorMedix Buyback And REZZAYO Data Shape Valuation And Risk Profile - Yahoo Finance
CorMedix Inc Azioni (CRMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):